IPSC centurytx.com: Projected Price to Earnings

Corporate company logo of Century Therapeutics, Inc. (IPSC)

The current forward P/E ratio of Century Therapeutics (IPSC) demonstrates a transition from the clinical testing stage to the establishment of a commercial base, with the metric reaching 0.00. Century Therapeutics creates universal cell products for mass medical application. Development relies on the work of elite geneticists, who are attracted by generous stock options and unlimited R&D resources.

Century Therapeutics - IPSC Future Price to Earnings Multiple (period 07/04/2022 - 11/15/2026)

Summary analytical data breakdowns for centurytx.com (IPSC)

- stock quotes and analyst forecast:
Stock Price Century Therapeutics, Inc.|IPSC - Analyst Target Range
- company stock capitalization data:
Market Valuation Century Tx|IPSC - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Century Therapeutics|IPSC - Accounting Value of Company|Market Capitalization to Book Value Ratio centurytx.com|IPSC - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Century Therapeutics|IPSC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Century Therapeutics, Inc.|IPSC - Company Debts|Debt to Book Capitalization Ratio IPSC|IPSC - Company Long-Term Debt|Company Current Liabilities Century Therapeutics|Quick Ratio centurytx.com
- financial results and valuation multiples details:
IPSC - Annual Net Income|Projected Future Earnings Century Therapeutics|IPSC - Market Cap to Earnings|Future Price to Earnings Century Therapeutics Inc|IPSC - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Century Tx|IPSC - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Century Therapeutics|IPSC - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months centurytx.com|IPSC - Net earnings per one share growth for the current year|Earnings growth forecast for next year Century Therapeutics
- sales volume and revenue information:
IPSC - Company Sales Revenue|Projected Sales Volume Century Therapeutics|IPSC - Price to Sales|Price-to-Projected Revenue Ratio Century Therapeutics
General company analysis:IPSC Century Therapeutics Inc
Brand item of Century Therapeutics

For Century Therapeutics (IPSC), which develops cancer treatment methods based on a single scientific and technological foundation, the forward P/E serves as a gauge of market expectations regarding the monetization of its cellular platforms. By analyzing the company's forward P/E trend, an investor assesses the ratio of current market capitalization to projected net income, where a high multiple signals a priced-in premium for a future technological breakthrough.

Competing companies

Forward P/E Multiple LEGN|Sana Biotechnology (SANA) - Forward Price to Earnings Multiple|Autolus Therapeutics PLC - Projected Price to Earnings|Allogene (ALLO) - Projected Price to Earnings Ratio|RNAC: Projected Price to Earnings|Future Price to Earnings Multiple CLLS (cellectis.com)|CRBU: Forward P/E Multiple|Projected Price to Earnings Ratio Instil Bio Inc (TIL)|GNTA (Genenta Science SpA) - Forward P/E Multiple|Projected Price to Earnings Ratio jaspertherapeutics.com JSPR|Future Price to Earnings Senti Biosciences (SNTI)|Future Price to Earnings ADAP (Adaptimmune Therapeutics plc)|Future Price to Earnings CERo Therapeutics Holdings Inc. CERO|alaunos.com - Future Price to Earnings|ACHL: Projected Price to Earnings|Future Price to Earnings Multiple CRGX (CARGO Therapeutics)|PSTX: Forward P/E Multiple|Forward Price to Earnings Multiple 2seventy bio TSVT|GRCL (gracellbio.com) - Forward P/E Multiple